Engflag

Afamelanotide

Quick links to important sections

Afamelanotide

Afamelanotide_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Afamelanotide

Afamelanotide is a highly specialized, prescription-only medicine defined as a synthetic tridecapeptide and structural analogue of the body’s own alpha-Melanocyte-stimulating hormone (alpha-MSH).

Property Description
Active ingredient Afamelanotide (as acetate)
Form Subcutaneous Implant (bioresorbable)
Pharmacological class Melanocortin Receptor Agonist
General purpose To enhance intrinsic photoprotection
Origin Synthetic (chemically engineered peptide)

What Type of Medicine is Afamelanotide?

Afamelanotide is a unique synthetic peptide drug designed to activate the skin’s biological defense system.

The compound belongs to the pharmacological class of melanocortin receptor agonists. This synthetic structure differentiates it by providing increased stability compared to the natural alpha-MSH. Its targeted action on the MC1R receptor allows the substance to maintain activation of the pigmentation pathways over a controlled duration.

How is Afamelanotide Prepared and Delivered?

The medicine is delivered exclusively as a solid, bioresorbable subcutaneous implant, which provides a long-term, sustained internal administration.

This distinctive dosage form is a single-ingredient product, differing significantly from standard injections or oral treatments. It consists of the active compound embedded within a biodegradable PLGA polymer matrix. The implant is specifically engineered for sustained drug release, a key differentiating factor that ensures a consistent concentration of Afamelanotide is available internally over many weeks, eliminating the need for frequent patient dosing.

What is the General Purpose of Afamelanotide?

The primary purpose of the medicine is to activate melanocytes, enhancing the skin’s inherent protection against light exposure.

Afamelanotide achieves this through targeted melanogenesis stimulation. By binding to the MC1R receptor, it drives the increased production of eumelanin, the dense, highly protective form of melanin. The general purpose is to increase the skin's overall tolerance to light by creating an internal biological shield throughout the skin.

Regulatory References

  1. European Medicines Agency (EMA)

What side effects are possible with Afamelanotide?

Possible Side Effects and Safety Information

The following safety information is strictly based on data documented in official government regulatory sources, such as the FDA Prescribing Information and the EMA Summary of Product Characteristics.

Frequency-Classified Adverse Reactions

Adverse reactions are classified by how often they occurred in clinical studies:

Frequency Examples of Adverse Reactions
Very Common (ge 1 in 10) Implant site reaction (e.g., pain, bruising, discoloration), Headache, Nausea
Common (ge 1 in 100 to <1 in 10) Skin hyperpigmentation, Melanocytic nevus (new or changed moles), Oropharyngeal pain, Cough, Fatigue, Dizziness

System-Organ Classes Affected

Side effects are commonly observed in the following body systems:

  • General Disorders and Administration Site Conditions: Implant site reactions (pain, haematoma, erythema), fatigue.
  • Skin and Subcutaneous Tissue Disorders: Skin hyperpigmentation, melanocytic nevus, skin irritation, and pigmentation disorders.
  • Gastrointestinal Disorders: Nausea, abdominal pain, oropharyngeal pain.
  • Nervous System Disorders: Headache, dizziness, somnolence.

Safety-Related Restrictions and Monitoring

Serious Safety Risks: Serious hypersensitivity reactions, including anaphylaxis, have been reported in post-marketing experience. Patients are often monitored for 30 minutes following implantation.

Safety Restrictions (Contraindications): The medicine is restricted and must not be used in individuals with a known allergy (hypersensitivity) to afamelanotide or its components, or those with severe hepatic (liver) or renal (kidney) disease.

Mandatory Skin Monitoring: Because the medicine increases skin pigmentation and can affect pre-existing moles, regulatory documents mandate regular full-body skin examinations (e.g., twice yearly) by a healthcare provider to monitor all pigmentary lesions and skin abnormalities.

Overdose and Emergency Response

The official regulatory profile for Afamelanotide is defined by specific statements regarding both classical overdosage and mandated emergency responses to severe acute events.

The official prescribing information, including the Summary of Product Characteristics, clearly states that there are no data available on the symptoms or treatment protocols for an overdose of Afamelanotide. Consequently, no specific clinical manifestations, laboratory findings, or physiological changes related to excessive dosage are formally documented in the regulatory literature. Due to this absence of information, general supportive and symptomatic care would be indicated if an overdose were suspected. Furthermore, no specific antidote is officially known or described.

When to Seek Immediate Medical Help

While classical overdose is not described, the official labeling mandates specific actions for acute, severe reactions. Urgent medical attention must be sought immediately if a patient experiences signs of a serious hypersensitivity reaction, including anaphylaxis, which are documented risks.

In these life-threatening situations, regulators require immediate therapeutic intervention. The treating professional must initiate appropriate therapy and is specifically advised to remove the subcutaneous implant if deemed necessary to manage the reaction. Following any serious hypersensitivity event, the patient must not receive any further treatment with Afamelanotide, as specified in the official Prescribing Information. These requirements highlight the mandatory nature of emergency response for severe acute events.

Therapeutic Uses of Afamelanotide

Afamelanotide is a therapy relevant for the management of adult patients with Erythropoietic Protoporphyria (EPP) and related X-linked Protoporphyria (XLPP), conditions where patients experience severe light intolerance.

Targeting Severe Photosensitivity in Protoporphyrias

Afamelanotide is generally used to manage intense light sensitivity, a condition where exposure to light leads to symptoms related to physical discomfort, such as severe burning pain, stinging, and pronounced skin redness. This therapy is commonly used across conditions presenting with acute or recurrent episodes of phototoxicity. The therapy is relevant for managing light sensitivity, a key symptom of the condition.

Enhancing Functional Light Tolerance

The medication is relevant for easing symptoms that interfere with daily functioning, primarily the profound inability to sustain light exposure without pain. By providing supportive relief and assisting with symptomatic management, Afamelanotide may contribute to increased pain-free light exposure time. This supports general well-being during symptomatic phases and may assist with maintaining functional stability. The medication is commonly used during phases of increased distress or discomfort, often corresponding to seasonal periods of heightened sunlight.

Quick Fact: Relevant for Managing Severe Phototoxic Pain

Regulatory References

  1. European Medicines Agency (EMA) therapeutic overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Afamelanotide?

The eligibility for Afamelanotide is strictly defined by regulatory guidelines, focusing on the approved condition, age, and pre-existing medical conditions.

Eligibility and Exclusion Criteria

Classification Population Details (as per Labeling)
Approved Population Adult patients (aged 18 years and older) diagnosed with Erythropoietic Protoporphyria (EPP) or X-linked Protoporphyria (XLPP).
Contraindicated Groups Patients with known hypersensitivity to afamelanotide or any component of the implant. Also, patients with severe hepatic disease (liver impairment) and renal impairment (kidney impairment) (as per European labeling).

Age and Conditional Use Limitations

  • Pediatric Use: Use is not recommended in children and adolescents under 18 years of age because the safety and efficacy of the medicine have not been established in this population (Source: FDA, EMA).
  • Geriatric Use: Use in patients over 70 years of age is not recommended due to limited clinical data.
  • Pregnancy and Breastfeeding: Afamelanotide should not be used during pregnancy or breastfeeding. Women of childbearing potential must use effective contraception during and for three months after treatment.
  • Melanoma History: Patients with a history of melanoma require special caution and mandatory, regular skin monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for afamelanotide defines its interaction profile primarily through the absence of expected systemic effects and a documented localized risk related to the subcutaneous implant procedure.

Documented Interaction Patterns

Classification Official Regulatory Finding
Systemic Pharmacokinetic Interactions Not Expected. Formal drug-drug interaction studies were not conducted. Regulatory assessment indicates that inhibition of CYP enzymes and major drug transporters is not anticipated, meaning afamelanotide is not expected to significantly alter the systemic exposure (AUC or Cmax) of co-administered medicines.
Localized Pharmacodynamic Interaction Co-administration with agents that reduce blood coagulation, such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Warfarin, or Acetylsalicylic acid, may increase the risk of bruising or bleeding specifically at the subcutaneous implantation site.
Contraindicated Combinations The product is contraindicated only in cases of known hypersensitivity to the active substance or to any of the implant's excipients.
Food or Alcohol Interactions None documented. Due to the medicine's delivery as a subcutaneous implant, no clinically significant interactions with food or alcohol are specified in the official labeling.
Timing Requirements None documented. There are no mandatory administration timing or separation rules specified in the prescribing information for any co-administered products.

This structure reflects the regulatory finding that systemic metabolic interactions are unlikely. Consequently, the primary documented restriction is related to procedural risk when co-administering medicines that affect blood coagulation.

Mechanism of Action

Afamelanotide is an analog of alpha-Melanocyte-Stimulating Hormone (alpha-MSH). The drug's mechanism initiates within the melanocytes, specialized skin cells responsible for pigment production. Afamelanotide works by selectively binding to and activating the Melanocortin 1 Receptor ( MC1R) expressed on the surface of these cells, thus acting as an agonist. This interaction is the initiating event of its pharmacodynamic action.

MC1R activation triggers an intracellular signaling cascade, specifically leading to the activation of adenylate cyclase. This enzyme rapidly increases the intracellular concentration of cyclic adenosine monophosphate ( cAMP), a critical second messenger. The elevated cAMP levels consequently activate key enzymes in the melanogenesis pathway, which enhances the production of eumelanin (dark, UV-absorbing pigment) relative to the lighter pheomelanin. This enhanced melanogenesis is the core system-level physiological modulation resulting from afamelanotide administration.

Dosage and Administration Information

How to Use Afamelanotide

Afamelanotide is administered under specific conditions that define its route, dosage, frequency, and handling.

Official Administration and Dosage

Administration Detail Official Requirement
Route of Administration Subcutaneous (SC) implantation only.
Dosage Form Single 16 mg bioresorbable implant.
Dosing Frequency One implant administered every two months.

Procedural and Contextual Instructions

The medicine is not self-administered; it must be implanted by a healthcare professional who is trained and proficient in the procedure.

Key procedural steps involve allowing the implant to gradually warm to ambient temperature before insertion and performing the procedure using an aseptic technique. The designated site for implantation is subcutaneously above the anterior supra-iliac crest.

Treatment is typically scheduled to begin prior to and during periods of expected or increased sunlight exposure, aligning the drug's sustained release with the patient’s symptomatic season. Following implantation, the patient is required to be monitored for 30 minutes.

Population-Specific Use

Administration is generally limited to adult patients (18 years and older). Use is not recommended for patients over 70 years of age due to insufficient clinical data, and efficacy has not been established for children and adolescents (under 18 years).

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section summarizes research evidence on afamelanotide for the prevention of phototoxicity in adult patients with Erythropoietic Protoporphyria (EPP). Studies examined its potential to reduce symptoms related to sun exposure.

Mechanism of Action: How it Might Work

Research was explored in studies regarding its potential mechanism of action. Afamelanotide is an analog of alpha-melanocyte stimulating hormone (alpha-MSH) that binds to and activates the melanocortin-1 receptor (MC1R). This activation is reported to increase the production of eumelanin, a photoprotective pigment in the skin. The increased eumelanin is theorized to attenuate UV and visible light penetration.

Efficacy Data from Randomized Controlled Trials (RCTs)

Multiple randomized, placebo-controlled clinical trials have evaluated afamelanotide. Primary studies reported that participants receiving the drug were observed to have greater pain-free light exposure compared to placebo groups. The primary endpoint in these trials involved the total duration of direct sunlight exposure between 10 AM and 6 PM on days when patients reported no pain.

  • One large-scale Phase III trial reported that the median cumulative time in direct sunlight on pain-free days over six months was higher in the afamelanotide group compared to the placebo group.
  • Secondary measures, including patient-reported Quality of Life (QoL) questionnaires specifically designed for EPP, also reflected differences favoring the afamelanotide group.

Safety and Tolerability

Commonly reported adverse events in clinical trials included implant site reactions and nausea. One meta-analysis summarized adverse effects reported over six months of continuous use and did not find a strong association with serious adverse events. Skin hyperpigmentation was also frequently observed, which is consistent with the drug's mechanism.

The research was conducted under specific trial conditions and did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently from younger subjects.

Key Studies & References

  1. Afamelanotide for Erythropoietic Protoporphyria (Multicenter, randomized, double-blind, placebo-controlled trials: CUV039 and CUV029)
  2. A Phase III, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients With Erythropoietic Protoporphyria (EPP) (NCT00979745)

How should Afamelanotide be stored and disposed of?

Storage and Handling Requirements

Afamelanotide implant must be stored under strictly controlled conditions, which are primarily managed by the healthcare provider.

Requirement Official Regulatory Mandate
Storage Temperature The product must be stored refrigerated, between 2 C and 8 C (36 F and 46 F).
Container & Protection Storage must be in the original, sealed amber glass vial to ensure packaging integrity and protect the contents.
Pre-Use Handling Before administration, the carton must be removed from the refrigerator to allow the implant to gradually warm up to ambient temperature.
Aseptic Condition The implant must be removed from the vial and handled only under aseptic conditions just prior to insertion.

Official Disposal Instructions

As the Afamelanotide implant is bioresorbable, it dissolves naturally in the body after successful administration. However, specific instructions exist for unadministered product:

  • Unused Product: If the implantation procedure is unsuccessful and the implant is confirmed to be outside the patient, the unused product must be discarded according to the established local requirements for pharmaceutical waste.
  • Environmental Status: Regulatory documents classify the product with a categorical exclusion from needing special environmental assessments for disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Afamelanotide found in:

A-Z Index: